1-9 of 9
Mark Acosta
Close
Sort by
Journal Articles

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Mark Acosta, PharmD, Arrash Darban, PharmD, MS, Matthew Gitlin, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5869.
https://doi.org/10.1182/blood-2019-124990
Published: 2019
Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4050.
https://doi.org/10.1182/blood-2019-127155
Published: 2019
Journal Articles

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Robert Stuver, MD, Niloufer Khan, MD, Marc Schwartz, Mark Acosta, Massimo Federico, MD, Christian Gisselbrecht, Frederick Lansigan, MD, Lauren C. Pinter-Brown, MD, Barbara Pro, MD, Andrei R. Shustov, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Salvia Jain, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2926.
https://doi.org/10.1182/blood-2018-99-112869
Published: 2018
Journal Articles

The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study

Steven I Park, MD, Steven M. Horwitz, MD, Francine M Foss, MD, Lauren C. Pinter-Brown, MD, Kenneth R. Carson, MD PhD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, MD, Marc Schwartz, Lisa A Bellm, Mark Acosta, Ranjana H. Advani, MD, Tatyana A Feldman, MD, Mary Jo Lechowicz, MD, Sonali M. Smith, MD, Frederick Lansigan, MD, Anil Tulpule, MD, Michael Craig, MD, John P. Greer, MD, Brad S Kahl, MD, Joseph W Leach, Neil Morganstein, MD, Carla Casulo, MD, Andrei R. Shustov, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 342.
https://doi.org/10.1182/blood.V130.Suppl_1.342.342
Published: 2017
Journal Articles

Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study

Frederick Lansigan, MD, Steven M Horwitz, MD, Lauren C Pinter-Brown, MD, Kenneth R Carson, MD, Andrei R Shustov, MD, Steven T. Rosen, MD, Barbara Pro, MD, Eric D. Hsi, MD, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A Bellm, MIM, Mark Acosta, PharmD, Francine M. Foss, MD
Journal: Blood
Blood (2016) 128 (22): 4150.
https://doi.org/10.1182/blood.V128.22.4150.4150
Published: 2016
Journal Articles

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Francine Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Eric Jacobsen, MD, Ranjana Advani, MD, Mitchell Smith, MD, PhD, Rami Komrokji, MD, Kelly Pendergrass, MD, Vanessa Bolejack, MPH, Karen Watts, Mark Acosta, PharmD
Journal: Blood
Blood (2007) 110 (11): 3449.
https://doi.org/10.1182/blood.V110.11.3449.3449
Published: 2007
Journal Articles

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD
Journal: Blood
Blood (2006) 108 (11): 2712.
https://doi.org/10.1182/blood.V108.11.2712.2712
Published: 2006
Journal Articles

Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve.

Myron S. Czuczman, MD, Lauren Pinter-Brown, Mary Jo Lechowicz, Nancy Bartlett, MD, Hillard Lazarus, John Lister, Andre Goy, MD, Stephen Kahanic, MD, Peter Rosen, MD, Mark Acosta, PharmD
Journal: Blood
Blood (2006) 108 (11): 4724.
https://doi.org/10.1182/blood.V108.11.4724.4724
Published: 2006
Journal Articles

A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis.

Francine M. Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Ranjana Advani, MD, Eric Jacobsen, MD, Mark Acosta, PharmD
Journal: Blood
Blood (2006) 108 (11): 2461.
https://doi.org/10.1182/blood.V108.11.2461.2461
Published: 2006